Growth-hormone axis: GHRH, GHRP, ghrelin receptor, and the GH/IGF-1 cascade

Detailed explanation

The growth-hormone axis is the neuroendocrine cascade by which the hypothalamus regulates the pulsatile release of growth hormone (GH, somatropin) from anterior-pituitary somatotrophs, which in turn drives the hepatic and peripheral synthesis of insulin-like growth factor 1 (IGF-1) and a wide array of downstream effects on protein synthesis, lipolysis, glucose metabolism, and tissue growth. The axis is regulated by two opposing hypothalamic peptides — growth-hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin (SST), which inhibits it — and is additionally modulated by ghrelin, the gastric-derived 'hunger hormone' that engages a distinct pituitary receptor to amplify GH pulsatility. The integrated activity of these three signals produces the characteristic pulsatile GH-release pattern, with overnight peaks driving the diurnal rhythm of IGF-1 production. GHRH is a 44-amino-acid hypothalamic peptide secreted by arcuate-nucleus neurons into the hypophyseal portal circulation. Binding the GHRH receptor (GHRHR, a class B G-protein-coupled receptor) on anterior-pituitary somatotrophs activates Gαs/adenylate cyclase signalling, raising intracellular cAMP and triggering protein kinase A-mediated phosphorylation of CREB. This drives transcription of the GH gene and pulsatile release of stored GH. GHRH-pathway stimulation respects the physiological negative-feedback loops — circulating IGF-1 and somatostatin tone both attenuate GHRH signalling — making GHRH-analogue therapy mechanistically more conservative than exogenous recombinant GH. Synthetic GHRH analogues (sermorelin, tesamorelin, CJC-1295) reproduce the receptor activation of native GHRH with extended pharmacokinetic profiles. The second activating arm is the GHRP (growth-hormone-releasing peptide) pathway, mediated by the growth-hormone secretagogue receptor (GHSR, the ghrelin receptor) — a Gq/PLC-coupled GPCR distinct from the GHRH receptor. GHRP activation raises intracellular calcium via IP₃ signalling, triggering GH release in a manner that is synergistic with — and partially independent of — GHRH-pathway stimulation. The class includes GHRP-2, GHRP-6, ipamorelin, hexarelin, and the orally bioavailable small-molecule MK-677 (ibutamoren). The dual-pathway architecture explains why combined GHRH-analogue + GHRP protocols (sermorelin + ipamorelin, CJC-1295 + ipamorelin) produce GH pulses materially larger than either pathway can elicit alone — the standard research approach for maximising endogenous GH release while preserving its pulsatile pattern. Downstream of pituitary GH release, GH binds the GH receptor (GHR) on hepatocytes and peripheral tissues, activating JAK2/STAT5 signalling to drive transcription of IGF-1 and IGF-binding proteins (notably IGFBP-3 and the acid-labile subunit ALS). Circulating IGF-1 mediates most of GH's anabolic effects on tissue growth via the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR signalling, while GH itself exerts direct lipolytic effects on adipose tissue and metabolic effects on glucose disposal. Pulsatile rather than continuous GH exposure preserves IGF-1 sensitivity and minimises receptor desensitisation — a key reason GH secretagogues are pharmacologically preferred over chronic recombinant GH in many research contexts. The distinct receptor architectures, signalling cascades, and downstream readouts of the GH axis give researchers a toolkit of pharmacologically separable interventions. GHRH analogues (sermorelin, tesamorelin, CJC-1295) activate the GHRHR/cAMP axis with extended half-lives — tesamorelin holds FDA approval for HIV-associated lipodystrophy, sermorelin is the prototype short-half-life GHRH analogue, and CJC-1295 (with or without DAC, drug affinity complex) extends half-life through albumin binding for sustained signalling. GHRPs (ipamorelin, hexarelin, GHRP-2, GHRP-6) activate the GHSR/Gq axis with varying receptor selectivity — ipamorelin is highly GH-selective with minimal cortisol/prolactin spillover, hexarelin has the largest acute GH-releasing capacity but cardiac-conditioning effects unique to its profile, and GHRP-6 retains the appetite-stimulating activity of native ghrelin. Combined administration of a GHRH analogue with a GHRP produces synergistic GH pulses that exceed either monotherapy. Key pre-clinical and clinical assays for GH-axis research include GH stimulation testing (timed serum GH measurements after secretagogue administration), 24-hour pulsatile GH profiling (frequent sampling to characterise pulse amplitude, frequency, and area-under-curve), serum IGF-1 and IGFBP-3 concentrations as integrated pharmacodynamic readouts, and downstream metabolic endpoints including fasting glucose, HOMA-IR for insulin sensitivity, and DEXA-measured body composition. For tesamorelin in HIV-lipodystrophy contexts, visceral adipose tissue volume by CT or MRI is the established efficacy endpoint. These peptides represent the principal research toolkit for studying the GH axis at the pharmacologically modifiable level of pituitary release rather than peripheral GH or IGF-1 substitution. The mechanistic separation between GHRH-pathway and GHRP-pathway peptides — and the synergistic dual-pathway protocols — defines the research-design space.